Sharda Cropchem Q3 PAT Skyrockets 366% on Agrochem Surge, Guides Robust Growth

CHEMICALS
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Sharda Cropchem Q3 PAT Skyrockets 366% on Agrochem Surge, Guides Robust Growth
Overview

Sharda Cropchem Limited reported a robust Q3 FY26 with revenue up 39% YoY to ₹1,289 cr, driven by a 48% surge in its agrochemical business. EBITDA climbed 59% YoY to ₹246 cr, and PAT rocketed 366% YoY to ₹145 cr, marking the highest-ever annual PAT in 9M FY26. Management confident in 15-20% revenue growth for FY27 and maintaining 18-20% EBITDA margins.

📉 The Financial Deep Dive

Sharda Cropchem Limited delivered an outstanding performance in Q3 FY26, marked by significant year-on-year growth across key financial metrics.

  • The Numbers:

    • Revenue surged by 39% YoY to ₹1,289 crores.
    • EBITDA grew by 59% YoY to ₹246 crores.
    • EBITDA margin stood at 19.1%, with gross margins expanding by 220 basis points YoY to 34.9%.
    • Profit After Tax (PAT) witnessed a phenomenal increase of 366% YoY to ₹145 crores.
    • The company achieved its highest-ever annual PAT in 9M FY26.
    • Volume growth was a healthy 14%.
    • The agrochemical business demonstrated exceptional strength, with 48% YoY growth, while the non-agrochemical segment saw a decline of 8.1%.
    • Planned capital expenditure for FY26 is ₹500 crores, with ₹399 crores invested by 9M FY26.
    • The company declared an interim dividend of ₹6 per share.
    • As of December 31, 2025, the company held ₹826 crores in cash and bank liquid investments, remaining net debt-free.
    • Working capital days improved to 70 days.

  • The Quality:
    The substantial growth in PAT, outpacing revenue growth, highlights strong operational efficiencies and margin expansion. The company's net debt-free status and substantial cash reserves of ₹826 crores indicate robust financial health and capacity for future investments and shareholder returns. The improved working capital management further bolsters liquidity.

  • The Grill:
    Management expressed confidence in sustaining growth momentum into Q4 FY26 and FY27, projecting revenue growth of 15-20% for FY27 and reiterating the FY26 EBITDA margin guidance of 18-20%, which is expected to hold for FY27. While optimistic, management did highlight "uncertainties in the product registration process" as a factor to monitor. Discussions are underway regarding increasing dividend payouts due to strong cash reserves.

🚩 Risks & Outlook

The primary risks identified include potential delays or challenges in the product registration process globally, which is crucial for the company's pipeline expansion. The performance of the non-agrochemical segment also warrants attention. However, the overall outlook remains positive, supported by a recovering global agrochemical market, a robust product registration pipeline (3,004 registrations and 1,076 applications pending), and strong financial discipline. Investors will watch for continued execution on product registrations and sustained growth in the core agrochemical business.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.